Eterna Therapeutics - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים ERNA

The complexity of cellular engineering and patent disputes are creating volatility within the sector. The year-over-year dynamics of commercial revenues on a rolling basis demonstrate current fluctuations, where -99.80 serves as the final level mark. Stable mRNA supply chains and innovative developments in oncology provide Eterna Therapeutics (ERNA) with growth potential and high product relevance by 2026.
Eterna Therapeutics, Inc. (ERNA) - פילוחי מדדים ודוחות פיננסיים

This indicator calculates the percentage change in revenue over the last twelve months relative to the same period last year, identifying real-time demand dynamics. For Eterna Therapeutics (ERNA), whose value is based on mRNA editing, the LTM annual sales growth rate serves as a marker for technology commercialization and confirms a fundamental business pivot amid ongoing clinical trials.